Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials
      QxMD      Google Scholar   
Citation:
JAMA Oncol vol 3 (8) 1043-1050
Year:
2017
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
DataSharing:
No
Book Volume:
6
Parents:
2571  
Children:
None
Program:
CCP
Primary Committee:
Health Outcome
Sec. Committees:
   
Pharmas:
 
Grants:
UG1 CA189829, U10 CA032291, U10 CA077658, U10 CA086726, U10 CA035279, U10 CA045808, U10 CA031946, U10 CA033601, U10 CA045389, U10 CA180854, U10 CA021060, U10 CA180821, P30 CA016086, U10 CA035421, U10 CA114558, U10 CA045418, U10 CA180836, UG1 CA189858, U10 CA180791, U10 CA037447, U10 CA180850, UG1 CA189817, UG1 CA189850, UG1 CA189830, U10 CA041287, UG1 CA189823, U10 CA047559, U10 CA077651, U10 CA180790, UG1 CA189972, U10 CA180882, UG1 CA189853, UG1 CA189819, P30 CA016359, U10 CA180867, U10 CA180838, U10 CA047642, U10 CA180844, U10 CA003927, U10 CA138561  
Corr. Author:
 
Authors:
                                                   
Primary Study
Secondary Studies:
CALGB-30607, CALGB-30610, CALGB-40502, CALGB-40503, CALGB-40601, CALGB-70501, CALGB-70604, CALGB-80405, CALGB-90401
Phases:
, 3, N/A
Keywords:
Article